News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle Genetics, Inc. (SGEN) Highlights Antibody-Drug Conjugate (ADC) Program And Technology Advances At American Association for Cancer Research


4/7/2014 8:57:52 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted research related to its antibody-drug conjugate (ADC) programs and technology in more than 15 presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held April 5 to 9, 2014 in San Diego, CA. The presentations describe promising advances that further enhance its ADC technology platform and review preclinical data from its proprietary SGN-CD19A and SGN-CD70A programs that support ongoing clinical development activities.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES